Lloyd Blankfein can’t imagine returning to Goldman Sachs
Former Goldman Sachs CEO Lloyd Blankfein said he couldn’t imagine returning to his old firm, disputing a news report that said Blankfein offered to return in some capacity. The New …
Former Goldman Sachs CEO Lloyd Blankfein said he couldn’t imagine returning to his old firm, disputing a news report that said Blankfein offered to return in some capacity. The New …
Jen-Hsun Huang, president and chief executive officer of Nvidia Corp., speaks during the company’s event at Mobile World Congress Americas in Los Angeles, California, U.S., on Monday, Oct. 21, 2019. …
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Monday’s key moments. 1. U.S. stocks rose Monday, …
Eli Lilly has had a great run, but UBS expects about 16% further upside in the coming months as a steady stream of positive news propels the stock higher and …
Rome ranked second on a recent list of best travel destinations for a digital detox. Piola666 | E+ | Getty Images Despite inflation, Gen Z and millennials are determined to …
Investors may want to consider using the recent weakness in Nvidia to snatch up shares of the artificial intelligence darling, according to some Wall Street analysts. The chipmaker sold off …
Banco Santander ‘s stock is in rare form this year. The Spanish lender’s U.S.-listed shares are up 32% in 2023, on pace for their biggest annual gain since 2009 — …
An AI (Artificial Intelligence) sign is seen at the World Artificial Intelligence Conference (WAIC) in Shanghai, China July 6, 2023. Aly Song | Reuters Market participants are “overconfident” about their …
Stablecoins may be crypto’s killer app, but there needs to be regulation in place to allow them to flourish – which could benefit the U.S. dollar, according to Brian Brooks, …
Bank of America thinks Kura Oncology could be a winner in blood cancer treatment, believing the stock could nearly triple in value. The bank initiated research coverage of the clinical-stage …